Cyclic peptides binding to targets of interest can be generated efficiently with powerful in vitro display techniques such as phage display or mRNA display. The cyclic peptide libraries screened with these methods are generated by altering in a combinatorial fashion the amino acid sequence of the peptides, the number of amino acids in the macrocyclic rings, and the cyclization chemistry.
Peptide macrocycles have a number of favorable properties that make them an attractive modality for the development of therapeutics. They can bind with high affinity and selectivity to protein targets, their degradation products are non-toxic, they offer different administration options, and they can be chemically synthesized. Another advantage is their fast development; they can be isolated from large combinatorial libraries generated by either chemical [1] or ribosomal synthesis. [2, 3] In vitro display techniques such as phage display or mRNA display allow the generation and screening of billions of peptide macrocycles in a short time and for a moderate cost. The chemical and structural diversity of peptide macrocycle libraries is obtained by varying the amino acid sequence, the number of amino acids, [4, 5] and the cyclization chemistry. [2, 6] For some protein targets, it has been difficult to generate high-affinity peptide macrocycles using in vitro display techniques, despite the enormous size and diversity of the libraries that is screened.
For therapeutic application, peptide macrocycles typically require a dissociation constant in the low nanomolar or picomolar range. A frequently chosen strategy to affinity mature in vitro evolved cyclic peptide ligands is to modify the side chains that make interactions with the target. The modular architecture of peptides, the commercial availability of many unnatural amino acids, and the availability of automated synthesis and purification methods allows efficient preparation of medium-sized libraries of such peptides. A limitation of strategies that rely on amino acid side chain modification can be the low rate of identifying peptides with improved activity. We had recently attempted to improve the binding affinity of the bicyclic peptide FXII618 (herein named bicyclic peptide 1, Figure 1a ), [7] a nanomolar inhibitor of the coagulation factor XII that was isolated by phage display. Following a strategy of substituting amino acid side chains in one position of the bicyclic peptide 1 at a time, we had to synthesize and test more than 50 peptides to find a first peptide variant with a better inhibitory activity (unpublished work).
In this work, we proposed to affinity mature the bicyclic peptide FXII inhibitor 1 by altering the backbone instead of the side chains. Specifically, we proposed to insert one or two carbon atoms in different positions of the macrocyclic rings. Peptides screened by phage display are composed of canonical amino acids that each contributes three atoms to the macrocyclic ring. More precisely, they contain 3*n+m backbone atoms wherein 'n' is the number of amino acids and 'm' the number of atoms contributed by the cyclization linker. In the phage display screen in which 1 was isolated, cyclic peptides with 3*n+m+1 or 3*n+m+2 backbone atoms were thus not sampled. We speculated that inserting carbon atoms in some sites of the backbone could potentially lead to small changes in the conformation of the macrocycle, and that this in turn could strengthen existing molecular interactions or allow the formation of new non-covalent contacts of 1 with FXII.
The strategy of inserting atoms into the backbone has been applied to several nature-derived cyclic peptides for studying the structure-activity relationship or enhancing the biological activity.
For example Ghadiri and co-workers had inserted single atoms into histone deacetylase (HDAC) inhibitors and measured their cytotoxic activity towards tumor cells and determined their structure. [8] The group of Muir had varied the macrocycle size of so called autoinducing peptides (AIPs) secreted by Staphylococcus aureus to study the structure-activity relationship. [9] Hansen and co-workers had extended the ring size of amphipathic cyclic peptides by different number of atoms to investigate the effect on antimicrobial and hemolytic activity. [10] Inserting or deleting single carbon atoms at different positions in macrocyclic rings of peptide ligands has not been used as a systematic approach for improving the binding affinity of in vitro evolved cyclic peptides.
A synthetically efficient way of generating cyclic peptides with additional carbon atoms in the rings is by replacing -amino acids with -amino acids that contain an additional carbon atom between the amino and carboxyl group (Figure 1b ). -to--amino acid substitution has been applied extensively to -helical peptides, following the observation that -amino acids can substantially improve their stability. [11] [12] [13] [14] In some -helical peptides, -amino acids had improved in addition to the stability the binding affinity, as for example in an analogue of parathyroid hormone receptor-1 agonist [15] or an engineered VEGF signaling inhibitor based on the Z-domain. [16] The strategy of -to--amino acid substitution was also applied to a handful of nature-derived cyclic peptides, including the above mentioned HDAC inhibitors and the AIPs. [8, 9] In this work, we chose to apply -amino acids to efficiently access variants of 1 having a single carbon atom inserted in different positions of the backbone.
In order to identify amino acid positions in which insertion of a carbon atom could potentially improve the binding affinity of bicyclic peptide 1, we synthesized two series of peptide variants: one having individual amino acids replaced by -alanine, and the other one having them replaced by glycine ( Table 1) . Comparison of the peptides containing -alanine and glycine in a specific position allowed understanding if an additional carbon atom in the specific position enhances binding to FXII, independent of the amino acid side chain. Unmodified bicyclic peptide 1 inhibited FXII with a Ki of 7 ± 0.4 nM. Substitution of Phe3, Arg4 and Leu5 to -alanine (2, 4, 6) or glycine (3, 5, 7) reduced the inhibitory activity by large factors (> 300-fold). For all three positions, the substitution to -alanine gave a larger drop in activity than the substitution to glycine, indicating that an additional carbon atom in these three positions of the main chain negatively affects the binding of bicyclic peptide 1. Substitution of Pro6 to -alanine (8) and glycine (9) reduced the affinity around 3-and 15-fold, respectively. The smaller loss in binding affinity found for the alanine variant suggested that insertion of one carbon atom in this position enhances the binding to FXII. Amino acid substitution at Arg8 had the opposite effect, giving a larger affinity drop for the peptide with the -alanine (19-versus 2-fold; 10, 11). In the positions Gln9 and Leu10, substitution to -alanine and glycine reduced the inhibitory activity more than 100-fold (12, 13, 14, 15) . Finally, in position Arg11, replacement of the amino acid with both, -alanine and glycine reduced the binding by a small factor (3-fold; 16 and 17).
Based on the results of the -alanine/glycine screen, we considered Pro6 and Arg11 as the most promising sites for -to--amino acid substitutions. -amino acids can have side chains at either the alpha (C2) carbon or the beta (C3) carbon and are denoted  2 -and  3 -residues, respectively.
Given that these carbon atoms can have R or S configuration, four diastereoisomeric -amino acids exist for any given side chain. We first substituted Pro6 with a range of cyclic -amino acids ( Table 2 ). All these substitutions reduced the inhibitory activity 80-fold or more (18-22). It is likely that the cyclic -amino acids imposed conformational constraints onto 1, hindering efficient binding to FXII. We subsequently synthesized peptides in which Pro6 was substituted with acyclic -amino acids having methyl groups linked to either the carbon 3, carbon 2 or the amino group (23-27; Table 2 ). We reasoned that the methyl groups could potentially replace interactions that were formed by the proline ring. Three of these peptides had double-digit inhibitory constants (23, 26, 27), but they all had weaker Kis than the peptide with -alanine in this position. The second position that was identified to tolerate the -alanine substitution reasonably well was Arg11. We replaced this amino acid with the  3 -amino acid structurally resembling best L-Arg (S configuration in C3;
(S)-β 3 -homoarginine) (28). This substitution yielded a peptide with a 4.7-fold improved Ki (we named the bicyclic peptide FXII700; 1.5 ± 0.1 nM; Table 2 ). Given that the two peptides 16 and 17, having -alanine and glycine in position Arg11, had a comparable affinity, it is likely that the affinity improvement achieved with the (S)-β 3 -homoarginine substitution resulted from interactions of the arginine side chain with FXII that are apparently better for the  3 -amino acid than for L-Arg.
Another efficient strategy for inserting carbon atoms into the macrocyclic rings of bicyclic peptide 1 is by substituting the cysteines with homocysteine or 5-mercapto-norvaline, having one and two additional carbons in the side chains, respectively (Figure 1b ). We synthesized six variants of 1, each having one of the three cysteines replaced by either of the two cysteine analogs ( Table 3) .
Replacement of the Cys12 with homocysteine and 5-mercapto-norvaline improved the binding 2.5-and 1.2-fold, respectively (Ki of 31 = 2.8 ± 0.5 nM, Ki of 34 = 5.8 ± 1.2 nM). Replacement of the other two cysteines conserved the binding affinity in the case of homocysteine (bicyclic peptides 29 and 30) and slightly reduced the binding for 5-mercapto-norvaline (bicyclic peptides 32 and 33). We named the bicyclic peptide 31 having the best Ki FXII701. Having found that cysteine analogues with longer side chains can improve the affinity, we tried also the conformationally constrained cyclic amino acid 4-mercapto-proline, having either 2S,4S or 2S,4R configuration ( Table 3 ). In these two amino acids, the sulfur and carbon We finally tested if the affinity-matured bicyclic peptides 28 and 31 were blocking better intrinsic coagulation pathway activation than the lead peptide 1. All three peptides dose-dependently prolonged the intrinsic coagulation time (aPTT) of human plasma wherein 28 and 31 were superior to 1 (Figure 2a ). The inhibitor with the highest affinity, bicyclic peptide 28 showed the best prolongation with an EC2x of 1.7 M as compared to peptide 1 which has an EC2x of 3.1 M. As the lead peptide 1, the affinity-matured inhibitors did not affect the extrinsic coagulation (PT),
showing that the high target selectivity was conserved (Figure 2b) .
In summary, we have proposed to improve the binding affinity of in vitro evolved cyclic peptide ligands by varying the size of the macrocyclic rings by one or two carbon atoms. We reasoned that this chemical space is not sampled by screening genetically encoded cyclic peptide libraries and could potentially offer a rich source for slightly improved ligands. Indeed, synthesis and screening of only 40 peptide variants of the bicyclic peptide FXII inhibitor 1 yielded several inhibitors with substantially improved Kis. 
Materials and methods

Materials
Peptide cleavage from the resin
The side chains were deprotected and the peptide cleaved from the Rink Amide AM resin by incubation with 5 mL cleavage solution (90% v/v TFA, 2.5% v/v 1,2-ethanedithiol, 2.5% w/v phenol, 2.5% v/v thioanisole, 2.5% v/v H2O) for 2 h with shaking. The resin was removed by vacuum filtration, and the peptides were precipitated with ice-cold diethyl ether (50 mL), incubated for 30 min at -20 °C, and pelleted by centrifugation for 5 min at 2700 g. The diethyl ether was discarded, and the precipitate was then washed twice with diethyl ether. The remaining solvent was evaporated at RT.
Peptide cyclization with TATA:
The crude peptide (typically ~ 50 mg) was dissolved in 6 mL 33% MeCN and 67% H2O (resulting in a concentration of ~ 3.5 mM). 1,3,5-triacryloyl-1,3,5-triazinane (TATA) (10 mM, 1.2 eq) in MeCN was added to the dissolved peptide. The reaction was started by the addition of degassed aqueous NH4HCO3 buffer (60 mM, pH = 8.0) until a final peptide concentration of 1 mM (1 h at 30 °C in water bath). The peptide was lyophilized.
Peptide purification by reversed-phase HPLC
Modified peptide powder was dissolved in 1 mL DMSO, 2 mL MeCN containing 0.1% TFA, and 7 mL H2O containing 0.1% TFA, and purified on a preparative C18 column (Vydac C18 TP1022 
Coagulation assays
Coagulation times (aPTT and PT) were determined in human plasma using a STAGO STart4
Coagulation analyzer (Diagnostica). Human single donor plasma was used (Innovative Research).
For the extrinsic coagulation, 50 L of plasma was placed in the incubating chamber of the instrument for 2 min at 37 °C. After incubation, 100 L of Innovin (recombinant human tissue factor, synthetic phospholipids, and calcium in stabilized HEPES buffer system; Dade Behring/Siemens) was added using the pipette connected to the instrument. Upon addition of this reagent the electromagnetically induced movement of a steel ball in the plasma is monitored. The time until the ball stops moving is recorded as coagulation time. For the intrinsic coagulation, 100
L of plasma was incubated with 100 L of Pathromtin* SL (silicon dioxide particles, plant phospholipids in HEPES buffer system, Siemens) for 2 min at 37 °C. Subsequently, the coagulation was triggered by addition of 100 L CaCl2 solution (25 mM, Siemens). Table 3 . Substitution of cysteines with homocysteine, 5-mercapto-norvaline and 4-mercaptoproline. Standard deviations were determined for peptides with Kis below 1 M and are indicated.
Tables
For peptides with Kis above 10 M, the remaining protease activity at a concentration of 10 µM is indicated in brackets. 
